{"a":[{"_":"Akeso, Summit’s ivonescimab extends lives in Keytruda head-to-head trial. What now?","$":{"href":"/pharma/akeso-summit-ivonescimab-extends-lives-keytruda-head-head-trial-what-now","hreflang":"en"}}]}

Data ReadoutpositiveivonescimabKeytrudaPositive

AI Analysis

Summary

Akeso and Summit Therapeutics' ivonescimab met the overall survival endpoint in a head-to-head trial against Merck's Keytruda, though the positive reception appears more measured than the prior progression-free survival win.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Head-to-head trial met overall survival endpoint versus Keytruda

Importance:7/10

Sentiment:

0.50

oncologyimmunotherapyhead-to-head trialoverall survivalPD-1VEGF

Read the original article

Published by FiercePharma on September 3, 2026 10:33 AM

Read Original